ProofPilota platform for automating digital protocols for clinical trials, added Bernadette Tosti to his executive leadership team in the role of chief product officer this week. Tosti has more than 15 years of experience in digital clinical trials, including leadership positions at Quest Diagnostics, IQVIA and Science 37.
Tosti will lead the product management, product design and patient retention organizations in partnership with the leadership team.
To read more, Press here.
Massachusetts Biotechnology Council (MassBio) Board of Directors indicated Kendall Berlin O’Connell as the new CEO and President of the organization. O’Connell has been a member of MassBio for 14 years, most recently as president and chief operating officer.
“Leading MassBio and supporting our members’ collective efforts to reshape global health is the honor of a lifetime,” said Berlin O’Connell. “Our members have created the largest life sciences ecosystem in the world. As their advocate and partner, our team at MassBio will ensure they have the tools and agility they need to identify the next life-changing breakthrough for patients.”
To read more, Press here.
Remix Therapeuticsa biotech company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease has appointed Dr. Christopher Bowden chief physician.
Bowden previously worked for Agios, where he served as strategic advisor and chief medical officer for eight years through 2022. As CMO, Bowden was responsible for the oncology clinical development and rare genetic disease portfolios that led to US approvals for the IDH inhibitors Idhifa and Tibsovo in AML, for Tibsovo in cholangiocarcinoma, and for Pyrukynd, a pyruvate kinase activator, for adults with pyruvate kinase deficiency. Prior to joining Agios, Bowden was Vice President of Oncology Product Development, Head of Franchise (Signaling Group) at Genentech, part of the Roche Group.
“We look forward to leveraging his extensive clinical experience as we develop programs from our REMaster platform into the clinic,” said Peter Smith, co-founder and CEO of Remix.
To read more Press here.
Genentech strengthened its marketing arsenal with two new employees.
Erica Taylor will serve as the company’s first chief marketing officer.
Ozgun (Oz) Demir has been appointed as Genentech’s first head of digital marketing.
Ashley Magarjisenior vice president and head of commercial portfolio, said, “Erika and Oz will transform our digital marketing capabilities at Genentech to provide an easier, faster and more seamless experience for customers and patients to access information about our products .”
To read more, Press here.
Blueprint drugs has appointed Dr. John Tsai to its board of directors. Tsai served as Chief Medical Officer at Novartis AG from 2018 to 2022. He has more than 20 years of experience in drug development and medical affairs at global pharmaceutical companies.
“John’s broad and deep experience in managing large pipelines and diverse portfolios for global pharmaceutical companies will make him a valuable board member as we develop multiple best-in-class clinical development programs across broad, established therapeutic areas,” said Kate Haviland, Blueprint Medicines CEO.
To read more, Press here.
Absolute careconcierge, a model of care led by a primary care physician has named a former U.S. Secretary of Health and Human Services Alex Hazard to its board of directors.
As HHS secretary, Azar led 85,000 employees, promoted transparency in health care goods and services, and expanded access to telehealth and rural health care for many Americans. Operation Warp Speed accelerated the creation and distribution of vaccines and therapeutics against Covid-19.
To read more, Press here.
Annovis Bioa clinical-stage drug platform company focused on neurodegenerative diseases has added two new hires to its senior leadership team. Dr. Michael Christie will serve as vice president of process chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.
Previously, Christy served as Senior Director of Chemical Process and R&D for Teva Pharmaceuticals, where he led large teams and managed four laboratories, while coordinating multiple projects and leading the chemical development, pilot plant and manufacturing laboratory functions. Prior to Teva, he worked at Cephalon.
Prohaska previously worked at Aravive Biologics, where he served as director of preclinical development and clinical operations support. He also worked at Furiex.
To read more, Press here.
Curve Healthdeveloper of the leading telehealth and analytics platform for seniors, today announced the appointment of Matthew Michela as CEO. Michela has been a healthcare leader for nearly four decades, having worked across multiple sectors including healthcare innovation, delivery, financing and patient care.
Previously, Michela served as President, CEO and Director of Life Image, a medical imaging network and exchange company. He also worked for Healthways and Care Management International, a provider of care management services that he co-founded in 2006.
To read more, Press here.
Sami has spent decades building relationships with CEOs and experienced investors, managing transactions and managing regional operations in the Middle East and North Africa and other geographies.
Prior to joining Patient Square, Sami was Executive Chairman and Head of MENA for Neuberger Berman and held a similar role at KKR where he was CEO and Head of MENA and Emerging Markets.
Nordic Consultinga global healthcare and technology consultancy, has expanded its international team with the promotion of Terry Lefort of president of Nordic International. It is also rented Kieran Hughes as president of Nordic’s European and Middle Eastern market and Thomas O’Shaughnessy as president of Healthtech, a Nordic global company operating in Canada. These changes follow the recent acquisition of Hygeian Consulting and plans for a new office in Dubai.
Prior to Nordic, Hughes worked at healthcare consulting, innovation and technology services firms where he executed international M&A and growth strategies.
O’Shaughnessy will help drive Healthtech development and growth, develop and execute business strategy and support the expansion of Nordic’s Meditech practice in United States.
To read more, Press here.
He will also lead the company’s Scientific Advisory Board, which helps ensure that Virgin Pulse’s technology and the experiences it supports are based on the most relevant scientific evidence and best practices.
Prior to Virgin Pulse, Jacques was the CEO and co-founder of CareTribe, a digital health platform supporting the needs of caregivers. It was acquired by Cleo in 2022.
photo: marchmeena29, Getty Images